139 related articles for article (PubMed ID: 9690660)
21. Use of neuroendocrine serum markers in the follow-up of patients with cancer of the prostate.
Angelsen A; Syversen U; Stridsberg M; Haugen OA; Mjølnerød OK; Waldum HL
Prostate; 1997 May; 31(2):110-7. PubMed ID: 9140124
[TBL] [Abstract][Full Text] [Related]
22. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression.
Cox ME; Deeble PD; Lakhani S; Parsons SJ
Cancer Res; 1999 Aug; 59(15):3821-30. PubMed ID: 10447001
[TBL] [Abstract][Full Text] [Related]
23. Relationship between neuroendocrine features and prognostic parameters in human prostate adenocarcinoma.
Bollito E; Berruti A; Bellina M; Mosca A; Leonardo E; Tarabuzzi R; Cappia S; Ari MM; Tampellini M; Fontana D; Gubetta L; Angeli A; Dogliotti L
Ann Oncol; 2001; 12 Suppl 2():S159-64. PubMed ID: 11762345
[TBL] [Abstract][Full Text] [Related]
24. Neuroendocrine differentiation in carcinomas of the prostate: do neuroendocrine serum markers reflect immunohistochemical findings?
Angelsen A; Syversen U; Haugen OA; Stridsberg M; Mjølnerød OK; Waldum HL
Prostate; 1997 Jan; 30(1):1-6. PubMed ID: 9018329
[TBL] [Abstract][Full Text] [Related]
25. The expression of neuropeptides in hyperplastic and malignant prostate tissue and its possible clinical implications.
Yu DS; Hsieh DS; Chen HI; Chang SY
J Urol; 2001 Sep; 166(3):871-5. PubMed ID: 11490236
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of neuroendocrine differentiation, proliferation activity and androgen receptor expression in prostate cancer.
Segawa N; Mori I; Utsunomiya H; Nakamura M; Nakamura Y; Shan L; Kakudo K; Katsuoka Y
Pathol Int; 2001 Jun; 51(6):452-9. PubMed ID: 11422807
[TBL] [Abstract][Full Text] [Related]
27. Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells.
Yuan TC; Veeramani S; Lin FF; Kondrikou D; Zelivianski S; Igawa T; Karan D; Batra SK; Lin MF
Endocr Relat Cancer; 2006 Mar; 13(1):151-67. PubMed ID: 16601285
[TBL] [Abstract][Full Text] [Related]
28. Prostate-specific antigen and prostate-specific acid phosphatase in neuroendocrine cells of prostate cancer.
Cohen RJ; Glezerson G; Haffejee Z
Arch Pathol Lab Med; 1992 Jan; 116(1):65-6. PubMed ID: 1370878
[TBL] [Abstract][Full Text] [Related]
29. Parathyroid hormone-related protein as a growth regulator of prostate carcinoma.
Dougherty KM; Blomme EA; Koh AJ; Henderson JE; Pienta KJ; Rosol TJ; McCauley LK
Cancer Res; 1999 Dec; 59(23):6015-22. PubMed ID: 10606251
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of neuroendocrine serum markers and PSA in irradiated patients with pN0 localized prostate cancer.
Lilleby W; Paus E; Skovlund E; Fosså SD
Prostate; 2001 Feb; 46(2):126-33. PubMed ID: 11170140
[TBL] [Abstract][Full Text] [Related]
31. Parathyroid hormone-related protein induces interleukin 8 production by prostate cancer cells via a novel intracrine mechanism not mediated by its classical nuclear localization sequence.
Gujral A; Burton DW; Terkeltaub R; Deftos LJ
Cancer Res; 2001 Mar; 61(5):2282-8. PubMed ID: 11280799
[TBL] [Abstract][Full Text] [Related]
32. PTHrP secretion is stimulated by CT and inhibited by CgA peptides.
Deftos LJ; Hogue-Angeletti R; Chalberg C; Tu S
Endocrinology; 1989 Jul; 125(1):563-5. PubMed ID: 2737164
[TBL] [Abstract][Full Text] [Related]
33. Neuroendocrine cells in human prostate over-express the anti-apoptosis protein survivin.
Xing N; Qian J; Bostwick D; Bergstralh E; Young CY
Prostate; 2001 Jun; 48(1):7-15. PubMed ID: 11391682
[TBL] [Abstract][Full Text] [Related]
34. Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy.
Weinstein MH; Partin AW; Veltri RW; Epstein JI
Hum Pathol; 1996 Jul; 27(7):683-7. PubMed ID: 8698312
[TBL] [Abstract][Full Text] [Related]
35. Focal neuroendocrine differentiation lacks prognostic significance in prostate core needle biopsies.
Casella R; Bubendorf L; Sauter G; Moch H; Mihatsch MJ; Gasser TC
J Urol; 1998 Aug; 160(2):406-10. PubMed ID: 9679888
[TBL] [Abstract][Full Text] [Related]
36. Divergent neuroendocrine differentiation in prostatic carcinoma.
di Sant' Agnese PA
Semin Diagn Pathol; 2000 May; 17(2):149-61. PubMed ID: 10839615
[TBL] [Abstract][Full Text] [Related]
37. Parathyroid hormone-related peptide expression in primary and metastatic liver tumours.
Roskams T; Willems M; Campos RV; Drucker DJ; Yap SH; Desmet VJ
Histopathology; 1993 Dec; 23(6):519-25. PubMed ID: 8314235
[TBL] [Abstract][Full Text] [Related]
38. Parathyroid hormone-related protein as a novel tumor marker in pancreatic adenocarcinoma.
Bouvet M; Nardin SR; Burton DW; Lee NC; Yang M; Wang X; Baranov E; Behling C; Moossa AR; Hoffman RM; Deftos LJ
Pancreas; 2002 Apr; 24(3):284-90. PubMed ID: 11893937
[TBL] [Abstract][Full Text] [Related]
39. The impact of diet and micronutrient supplements on the expression of neuroendocrine markers in murine Lady transgenic prostate.
Palmer J; Venkateswaran V; Fleshner NE; Klotz LH; Cox ME
Prostate; 2008 Mar; 68(4):345-53. PubMed ID: 18188867
[TBL] [Abstract][Full Text] [Related]
40. Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma.
Cussenot O; Villette JM; Valeri A; Cariou G; Desgrandchamps F; Cortesse A; Meria P; Teillac P; Fiet J; Le Duc A
J Urol; 1996 Apr; 155(4):1340-3. PubMed ID: 8632569
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
